|MDACC Study No:||2006-0706 (clinicaltrials.gov NCT No: NCT00413166)|
|Title:||Treatment of APL with all-trans retinoic acid, and arsenic +/- idarubicin|
|Principal Investigator:||Farhad Ravandi-Kashani|
|Treatment Agent:||Arsenic Trioxide; ATRA|
|Study Description:||The goal of this clinical research study is to learn if starting arsenic |
trioxide (ATO) therapy on Day 10 rather than Day 1 is more effective in
treating patients with newly-diagnosed APL. Researchers also want to learn if
theophylline can help to control APL.